RxDoctor Payments Data

Cheryl Smith

Family · Wilmington, NCNPI 1316083520

Payments from drug & device makers

$1,241in general payments, 2019–2025

Across 64 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$152
  • Sumitomo Pharma America, Inc.$125
  • Boston Scientific$122
  • Neurocrine Biosciences, Inc.$108
  • Biohaven Pharmaceuticals, Inc.$93
  • Amarin Pharma, Inc.$78
  • plus $564 from 20 others

What the payments were for

  • Food & beverage$1,241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,241 in reported general payments places this provider in the 70th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$134,273
Medicare patients
200
Services billed
1,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$47,206
TradjentaLinagliptin61$31,367
JanuviaSitagliptin Phosphate32$16,742
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,546
LinzessLinaclotide14$8,112
XareltoRivaroxaban14$7,802
MyrbetriqMirabegron19$7,102
TrulicityDulaglutide18$6,937
VascepaIcosapent Ethyl21$5,629
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,562
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$5,141
Atorvastatin Calcium282$5,052
Potassium Chloride224$4,889
Albuterol Sulfate46$3,377
SymbicortBudesonide/Formoterol Fumarate13$3,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$63$47,20694 claims
Boehringer IngelheimTradjenta$15$31,36761 claims
GSKTrelegy Ellipta, Anoro Ellipta$42$16,10826 claims
AbbVieLinzess$11$8,11214 claims
Lilly USA, LLCTrulicity$26$6,93718 claims
AstraZenecaSymbicort$28$3,27113 claims
Sanofi-aventis U.S. LLCLantus$61$1,85920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,522 family providers in North Carolina.

Other family in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →